| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 56% | -7.7% | $90,804,603 | +$10,553,555 | 12,953,581 | +13% | Srinivas Akkaraju | 22 Dec 2025 |
| RTW INVESTMENTS, LP | 5.7% | $12,714,000 | 1,300,000 | RTW Investments, LP | 31 Dec 2025 | |||
| GILEAD SCIENCES, INC. | 3.9% | $4,715,740 | 723,273 | GILEAD SCIENCES, INC. | 18 Mar 2025 | |||
| Invus Global Management, LLC | 1.5% | $754,533 | 282,586 | Invus Public Equities, L.P. | 30 Jun 2025 | |||
| EcoR1 Capital, LLC | 1.1% | $1,315,201 | 201,718 | EcoR1 Capital, LLC | 31 Mar 2025 |
As of 31 Dec 2025, 51 institutional investors reported holding 17,996,162 shares of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS). This represents 78% of the company’s total 22,927,577 outstanding shares.
The largest institutional shareholders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) together control 77% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 56% | 12,948,081 | +13% | 11% | $109,281,804 |
| RTW INVESTMENTS, LP | 5.7% | 1,300,000 | 0.11% | $10,972,000 | |
| Paradigm Biocapital Advisors LP | 3.1% | 700,000 | 0.16% | $5,908,000 | |
| Siren, L.L.C. | 1.9% | 435,798 | +37% | 0.11% | $3,678,135 |
| Alyeska Investment Group, L.P. | 1.8% | 403,551 | 0.01% | $3,402,109 | |
| Ikarian Capital, LLC | 1.6% | 360,000 | 0.4% | $3,038,401 | |
| VANGUARD GROUP INC | 1.3% | 292,790 | +44% | 0% | $2,471,147 |
| Kalehua Capital Management LLC | 0.61% | 139,901 | 0% | 1.2% | $1,180,764 |
| ADAR1 Capital Management, LLC | 0.44% | 100,000 | 0.06% | $844,000 | |
| Woodline Partners LP | 0.44% | 100,000 | -59% | 0% | $844,000 |
| WHI TRUST Co LLC | 0.43% | 97,493 | 0% | 0.63% | $822,841 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.4% | 92,261 | 0.02% | $778,683 | |
| RAYMOND JAMES FINANCIAL INC | 0.39% | 88,436 | 0% | $746,400 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.38% | 87,751 | -22% | 0% | $740,618 |
| Redmile Group, LLC | 0.36% | 82,955 | 0% | 0.05% | $700,140 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.36% | 82,647 | +28% | 0% | $697,599 |
| 683 Capital Management, LLC | 0.35% | 80,590 | 0.06% | $680,180 | |
| MARSHALL WACE, LLP | 0.32% | 72,876 | +416% | 0% | $615,074 |
| Propel Bio Management, LLC | 0.18% | 42,053 | 0.3% | $354,927 | |
| Fortis Capital Advisors, LLC | 0.17% | 40,000 | 0% | 0.05% | $337,600 |
| Belpointe Asset Management LLC | 0.17% | 40,000 | 0% | 0.01% | $337,600 |
| BlackRock, Inc. | 0.17% | 38,454 | -4.8% | 0% | $324,552 |
| GOLDMAN SACHS GROUP INC | 0.15% | 34,303 | +53% | 0% | $289,518 |
| JANE STREET GROUP, LLC | 0.14% | 33,114 | 0% | $279,482 | |
| OMERS ADMINISTRATION Corp | 0.13% | 30,000 | 0% | $253,200 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 17,996,162 | $151,883,912 | +$39,427,360 | $8.44 | 51 |
| 2025 Q3 | 13,222,873 | $76,428,251 | +$1,455,559 | $5.78 | 31 |
| 2025 Q2 | 13,362,268 | $35,677,274 | -$2,639,077 | $2.67 | 29 |
| 2025 Q1 | 13,874,350 | $111,411,096 | +$111,410,076 | $8.03 | 31 |